CHR. OLESEN PHARMACEUTICALS A/S: Financial statements 2017
CVR: 32090168
Source: annual report 2017, Danish Business Authority
01/10/2016 – 30/09/2017
CHR. OLESEN PHARMACEUTICALS A/S (CVR 32090168) has filed annual accounts for 2017. In 2017, the company reported a gross profit of EUR 528,524 and a net result of EUR 127,982 compared with EUR 21,094 the year before. That is an increase of 33.7% compared with the year before. Equity in the 2017 report amounted to EUR -126,333. The company had 1 employee in the financial year.
- Gross Profit
- EUR 528,524
- Profit/Loss
- EUR 127,982
- Equity
- EUR -126,333
- Total Assets
- EUR 3,506,526
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | - | 529K EUR | 128K EUR | -126K EUR | 1 |
| 2016 | - | 395K EUR | 21K EUR | -254K EUR | 1 |
| 2015 | - | 326K EUR | -130K EUR | -295K EUR | 1 |
| 2014 | - | 125K EUR | 3.1M EUR | -212K EUR | 1 |
| 2013 | - | 734K EUR | -1.3M EUR | -3.3M EUR | 2 |
Official annual report
Keep an eye on CHR. OLESEN PHARMACEUTICALS A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
CHR. OLESEN PHARMACEUTICALS A/S has published its annual report for 2016. Gross profit came to DKK 395,285, and the net result was DKK 21,094.
About CHR. OLESEN PHARMACEUTICALS A/S
CHR. OLESEN PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Gentofte, founded in 2009. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Christian Dam Olesen, Mads Christian Olesen and Phillip Christian Dam Quitzau Olesen. The board consists of Tobias Facklam (chair), Christian Dam Olesen and Fabian von Volkmann. The company is owned by CHR. OLESEN A/S and SVVF UG & Co. KG. The company has 2 employees (2026). In 2025, the company reported a gross profit of EUR 1,210,782 and a net result of EUR 237,447 compared with EUR 70,556 the year before. Equity in the 2025 report amounted to EUR 1,744,707.
